Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015152:Blotting, Northern; D015153:Blotting, Western; D045744:Cell Line, Tumor; D003094:Collagen / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D006801:Humans; D007797:Laminin / Q000494:pharmacology; D009361:Neoplasm Invasiveness; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D011401:Promoter Regions, Genetic; D011509:Proteoglycans / Q000494:pharmacology; D011743:Pyrimidines / Q000008:administration & dosage*; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors*; D055293:Receptors, Urokinase Plasminogen Activator; D013997:Time Factors; D014162:Transfection; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
C412373:AG 1879; D000970:Antineoplastic Agents; D004338:Drug Combinations; D007797:Laminin; C492461:NI-5.12; C524898:PLAUR protein, human; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D011509:Proteoglycans; D011743:Pyrimidines; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; C059485:matrigel; D003094:Collagen; D019061:src-Family Kinases